NMIN
PEOPLE
NMIN leverages the research and entrepreneurial excellence of a pan-Canadian, multidisciplinary team.
NMIN’s Board of Directors (BoD) provides governance and monitors progress towards strategic goals. The BoD receives input from two Advisory Committees: the Executive & Nominating Committee, and the Finance & Audit Committee.
NMIN’s Management Team consists of the Scientific Director & CEO, the Associate Scientific Director, and the Executive Director.
NMIN’s Research program receives oversight and strategic direction from the Research Management Committee (RMC). Each of the program’s three Themes and two Core Facilities are further overseen by two Co-leaders.
The RMC receives input from three committees: the KTEE Advisory Committee, the HQP Program Advisory Committee (HPAC), and the Executive Committee of the NMIN HQP Network (NHN).
The Administrative Centre Team provides support to the Research and the HQP programs, and implements the network’s administration, operations, IP, and communications cores on a day-to-day basis.
![](https://www.nanomedicines.ca/wp-content/uploads/2021/01/org-2-1024x925.png)
NMIN
PEOPLE
NMIN leverages the research and entrepreneurial excellence of a pan-Canadian, multidisciplinary team.
NMIN’s Board of Directors (BoD) provides governance and monitors progress towards strategic goals. The BoD receives input from two Advisory Committees: the Executive & Nominating Committee, and the Finance & Audit Committee.
NMIN’s Management Team consists of the Scientific Director & CEO, the Associate Scientific Director, and the Executive Director.
NMIN’s Research program receives oversight and strategic direction from the Research Management Committee (RMC). Each of the program’s three Themes and two Core Facilities are further overseen by two Co-leaders.
The RMC receives input from three bodies: the Commercialization Advisory Board (CAB), the HQP Program Advisory Committee (HPAC), and the Executive Committee of the NMIN HQP Network (NHN).
The Administrative Centre Team provides support to the Research and the HQP programs, and implements the network’s administration, operations, IP, and communications cores on a day-to-day basis.
![](https://www.nanomedicines.ca/wp-content/uploads/2021/01/org-3.png)
NMIN
GOVERNANCE
Board of Directors
NMIN’s Board of Directors (BoD) provides governance and monitors progress towards strategic goals.
The BoD includes 10 individuals with leadership experience in areas ranging from law to corporate management. Committees of the Board include the Board Executive, Board Nomination, Audit and Finance, Conflict of Interest, and Ethics Advisory committees. Members of the BoD also form adhoc committees or special task forces as needed.
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/IH.jpg)
CHAIR: Inès Holzbaur
Co-Founder & Managing Partner, AmorChem
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c.jpg)
Pieter Cullis
Professor, Department of Biochemistry and Molecular Biology, UBC
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/Lesley-Esford.jpeg)
VICE-CHAIR: Lesley Esford
Board Director, Innovate BC; Chair, NMIN Finance & Audit Committee
![](https://www.nanomedicines.ca/wp-content/uploads/2021/04/Fernandez.jpg)
Rachel Fernandez
Associate Vice-President, Research & Innovation, University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/IH-300x300.jpg)
CHAIR: Inès Holzbaur
Co-Founder & Managing Partner, AmorChem
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/Vanessa_Grant.jpg)
Vanessa Grant
Partner, Norton Rose Fulbright Canada LLP
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/DavidMartin-768x768.jpg)
David Martin
Managing Director & Head of Equity Research, Bloom Burton & Co
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/Parimal.jpg)
Parimal Nathwani
President and CEO
TIAP
![](https://www.nanomedicines.ca/wp-content/uploads/2019/06/GilbertWalker.jpg)
Gilbert Walker
Scientific Director & CEO
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Jennyfer.jpg)
Jennyfer Zapata-Farfan
Observer: President & Chair, NHN Executive Committee
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/allen.jpg)
Christine Allen
Associate Vice-President & Vice-Provost, Strategic Initiatives, University of Toronto; Scientific Director & CEO, NMIN
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/allen.jpg)
Christine Allen
Associate Vice-President & Vice-Provost, Strategic Initiatives, University of Toronto; Scientific Director & CEO, NMIN
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c-300x300.jpg)
Pieter Cullis
Professor, Department of Biochemistry & Molecular Biology
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/Lesley-Esford-300x300.jpeg)
VICE-CHAIR: Lesley Esford
Board Director, Innovate BC; Chair, NMIN Finance & Audit Committee
![](https://www.nanomedicines.ca/wp-content/uploads/2021/04/Fernandez-300x300.jpg)
Rachel Fernandez
Associate Vice-President, Research & Innovation, University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/Vanessa_Grant-300x300.jpg)
Vanessa Grant
Partner, Norton Rose Fulbright Canada LLP
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/DavidMartin-300x300.jpg)
David Martin
Managing Director & Head of Equity Research, Bloom Burton & Co
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/Parimal-300x300.jpg)
Parimal Nathwani
President and CEO, TIAP
MaRS Innovation
![](https://www.nanomedicines.ca/wp-content/uploads/2019/06/GilbertWalker-300x300.jpg)
Gilbert Walker
Scientific Director & CEO
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Jennyfer.jpg)
Jennyfer Zapata-Farfan
Observer: President & Chair, NHN Executive Committee
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/norma-sebestyen.jpg)
Norma Sebestyen
Advisor, Health Innovation, Strategy and Commercialization
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/yu-300x300.jpg)
Rebecca Yu
Vice President, Market Access and External Affairs, Takeda Canada
NMIN
NETWORK MANAGEMENT
Management Team
NMIN’s Scientific Leadership Team is comprised of the Scientific Director, the Associate Scientific Director, and the Executive Director, who provide strategic leadership and overall management.
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c.jpg)
Pieter Cullis
Scientific Director & CEO
![](https://www.nanomedicines.ca/wp-content/uploads/2019/06/GilbertWalker-300x300.jpg)
Gilbert Walker
Scientific Director & CEO
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/afsaneh.jpg)
Afsaneh Lavasanifar
Associate Scientific Director
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/Diana-Royce-300x300.jpg)
Diana Royce
Executive Director
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c-300x300.jpg)
Pieter Cullis
Scientific Director & CEO
![](https://www.nanomedicines.ca/wp-content/uploads/2019/06/GilbertWalker-300x300.jpg)
Gilbert Walker
Scientific Director & CEO
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/afsaneh.jpg)
Afsaneh Lavasanifar
Associate Scientific Director
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/Diana-Royce-300x300.jpg)
Diana Royce
Executive Director
NMIN
research MANAGEMENT
Research Management Committee
With representatives from academic and industry partners, the Research Management Committee (RMC) is responsible for ongoing assessment of all projects and provides recommendations to the BoD regarding research priorities and budget allocations.
The RMC receives input from three committees: the Commercialization Advisory Board (CAB), the HQP Program Advisory Committee (HPAC), and the Executive Committee of the NMIN HQP Network (NHN).
![](https://www.nanomedicines.ca/wp-content/uploads/2021/04/TerryAllen.jpg)
CHAIR: Terry M Allen
Professor Emerita, Pharmacology & Oncology, University of Alberta and Visiting Professor, Biochemistry & Molecular Medicine, University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/bally.jpg)
Marcel Bally
Theme 1 & PharmaCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/05/nicolas-bertrand.jpg)
Nicolas Bertrand
Associate Professor
Université Laval
![](https://www.nanomedicines.ca/wp-content/uploads/2021/10/Blakney.jpg)
Anna Blakney
Grand Challenges Thrust 2 Co-leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2021/04/TerryAllen-300x300.jpg)
CHAIR: Terry M Allen
Professor Emerita, Pharmacology & Oncology, University of Alberta and Visiting Professor, Biochemistry & Molecular Medicine, University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/04/allen-300x300.jpg)
Christine Allen
Scientific Director & CEO, NMIN
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/bally-300x300.jpg)
Marcel Bally
Theme 1 & PharmaCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/05/nicolas-bertrand-1-300x300.jpg)
Nicolas Bertrand
Associate Professor
Université Laval
![](https://www.nanomedicines.ca/wp-content/uploads/2021/10/Blakney-300x300.jpg)
Anna Blakney
Grand Challenges Thrust 2 Co-leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Warren-Chan-300x300.jpg)
Warren Chan
Theme 3 Co-leader
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2021/06/Connie-Chen-300x300.jpg)
Connie Chen
Senior Director, Strategy & Corporate Development
FACIT
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c-300x300.jpg)
Pieter Cullis
Theme 2 & NanoCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/ho-300x300.jpg)
Emmanuel Ho
Associate Professor
University of Waterloo
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/christian-300x300.jpg)
Christian Kastrup
Theme 2 & NanoCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Warren-Chan.jpg)
Warren Chan
Theme 3 Co-leader
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2021/06/Connie-Chen.jpg)
Connie Chen
Senior Director, Strategy & Corporate Development
FACIT
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c.jpg)
Pieter Cullis
Theme 2 & NanoCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/ho.jpg)
Emmanuel Ho
Associate Professor
University of Waterloo
![](https://www.nanomedicines.ca/wp-content/uploads/2019/06/kelley-300x300.jpg)
Shana Kelley
Theme 3 Leader
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2023/11/Star-cropped-300x300.jpg)
Shyh-Dar (Star) Li
Theme 1 & PharmaCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/afsaneh-300x300.jpg)
Afsaneh Lavasanifar
Associate Scientific Director
University of Alberta
![](https://www.nanomedicines.ca/wp-content/uploads/2021/11/LL-Headshot-300x300.jpg)
Larry Lynd
EHTA Platform Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/DavidMartin-768x768.jpg)
David Martin
Board Representative
NMIN Board Member
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/Michel_Meunier.jpg)
Michel Meunier
Theme 3 Co-leader
École Polytechnique de Montréal
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/maurer-n-300x300.png)
Norbert Maurer
External
Evonik Transferra
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/christian.jpg)
Christian Kastrup
Theme 2 & NanoCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/11/Star-cropped-768x768.jpg)
Shyh-Dar (Star) Li
Theme 1 & PharmaCore Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/afsaneh.jpg)
Afsaneh Lavasanifar
Associate Scientific Director
University of Alberta
![](https://www.nanomedicines.ca/wp-content/uploads/2021/11/LL-Headshot.jpg)
Larry Lynd
eHTA Platform Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/ONeill-300x300.jpg)
David O’Neill
External
FACIT
![](https://www.nanomedicines.ca/wp-content/uploads/2019/06/GilbertWalker-300x300.jpg)
Gilbert Walker
Scientific Director & CEO
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/Kaley2-300x300.jpg)
Kaley Wilson
Director, Business Development
Quark Venture
![](https://www.nanomedicines.ca/wp-content/uploads/2021/10/karen3-300x300.jpg)
Karen Chan
Observer
NanoCore Operational Lead
![](https://www.nanomedicines.ca/wp-content/uploads/2021/11/Cheng_Large-300x300.jpg)
Miffy Cheng
Observer
Theme 2 Research & KTEE Accelerator
![](https://www.nanomedicines.ca/wp-content/uploads/2020/06/DavidMartin-768x768.jpg)
David Martin
Board Representative
NMIN Board Member
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/Michel_Meunier.jpg)
Michel Meunier
Theme 3 Co-leader
École Polytechnique de Montréal
![](https://www.nanomedicines.ca/wp-content/uploads/2019/06/GilbertWalker.jpg)
Gilbert Walker
Scientific Director & CEO
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/Kaley2.jpg)
Kaley Wilson
Director, Business Development
Quark Venture
![](https://www.nanomedicines.ca/wp-content/uploads/2021/10/karen3.jpg)
Karen Chan
Observer
NanoCore Operational Lead
![](https://www.nanomedicines.ca/wp-content/uploads/2021/11/Cheng_Large.jpg)
Miffy Cheng
Observer
Theme 2 Research & KTEE Accelerator
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Dragojlovic.jpg)
Nick Dragojlovic
Observer
eHTA Technical Lead
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Dos-Santos_Nancy.jpg)
Nancy Dos Santos
Observer
PharmaCore Operational Lead
![](https://www.nanomedicines.ca/wp-content/uploads/2021/04/noun_profile_2942064-768x768.png)
Sara Esam
Observer
NCE Secretariat
![](https://www.nanomedicines.ca/wp-content/uploads/2023/10/ramya-768x768.jpg)
Ramya Kannan
Observer
Theme 1 Research & KTEE Accelerator
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Valic.jpg)
Michael Valic
Observer
NHN Vice-President
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Zia.jpg)
Nashmia Zia
Observer
Theme 3 Research & KTEE Accelerator
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Dos-Santos_Nancy-300x300.jpg)
Nancy Dos Santos
Observer
PharmaCore Operational Lead
![](https://www.nanomedicines.ca/wp-content/uploads/2021/04/noun_profile_2942064-300x300.png)
Sara Esam
Observer
NCE Secretariat
![](https://www.nanomedicines.ca/wp-content/uploads/2023/10/ramya-300x300.jpg)
Ramya Kannan
Observer
Theme 1 Research & KTEE Accelerator
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Zia-300x300.jpg)
Nashmia Zia
Observer
Theme 3 Research & KTEE Accelerator
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Valic-300x300.jpg)
Michael Valic
Observer
NHN Vice-President
Research Theme & Core Facilities Leaders
NMIN research is organized into three themes, led by Theme Leaders: Targeted Drug Delivery, Gene Therapy, and Diagnostics, each consisting of up to 10 projects. The research themes are supported by two core facilities led by Core Leaders: NanoCore and PharmaCore
Theme 1: Targeted Drug Delivery
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/bally.jpg)
Marcel Bally
Theme Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/11/Star-cropped-768x768.jpg)
Shyh-Dar (Star) Li
Theme Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/10/ramya-768x768.jpg)
Ramya Kannan
Theme 1 Research & KTEE Accelerator
Theme 2: Gene Therapy
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c.jpg)
Pieter Cullis
Theme Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/christian.jpg)
Christian Kastrup
Theme Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2021/11/Cheng_Large.jpg)
Miffy Cheng
Theme 2 Research & KTEE Accelerator
Theme 1: Targeted Drug Delivery
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/bally-300x300.jpg)
Marcel Bally
Theme Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/11/Star-cropped-300x300.jpg)
Shyh-Dar (Star) Li
Theme Co-Leader
University of British Columbia
Theme 2: Gene Therapy
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c-300x300.jpg)
Pieter Cullis
Theme Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/christian-300x300.jpg)
Christian Kastrup
Theme Co-Leader
University of British Columbia
Theme 3: Diagnostics
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Warren-Chan.jpg)
Warren Chan
Theme Co-Leader
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/Michel_Meunier.jpg)
Michel Meunier
Theme 3 Co-Leader
École Polytechnique de Montréal
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Zia.jpg)
Nashmia Zia
Theme 3 Research & KTEE Accelerator
Theme 3: Diagnostics
HQP Program
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Warren-Chan-300x300.jpg)
Warren Chan
Theme Co-Leader
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2019/07/Michel_Meunier-300x300.jpg)
Michel Meunier
Theme Co-Leader
![](https://www.nanomedicines.ca/wp-content/uploads/2020/05/MarkP-crop-300x300.jpg)
Mark Pereira
Theme Accelerator
University of Toronto
NanoCore
PharmaCore
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c.jpg)
Pieter Cullis
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/christian.jpg)
Christian Kastrup
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2021/10/karen3.jpg)
Karen Chan
Core Operational Lead
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/bally.jpg)
Marcel Bally
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/11/Star-cropped-300x300.jpg)
Shyh-Dar (Star) Li
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Dos-Santos_Nancy.jpg)
Nancy Dos Santos
Core Operational Lead
BC Cancer Agency
ieHTA
PharmaCore
![](https://www.nanomedicines.ca/wp-content/uploads/2021/11/LL-Headshot.jpg)
Larry Lynd
Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Dragojlovic.jpg)
Nick Dragojlovic
Technical Lead
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2021/10/karen3.jpg)
Karen Chan
Core Operational Lead
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/bally.jpg)
Marcel Bally
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Shyh-Dar.jpg)
Shyh-Dar (Star) Li
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Dos-Santos_Nancy.jpg)
Nancy Dos Santos
Core Operational Lead
BC Cancer Agency
NanoCore
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/pieter-c-300x300.jpg)
Pieter Cullis
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/christian-300x300.jpg)
Christian Kastrup
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2021/10/karen3-300x300.jpg)
Karen Chan
NanoCore Operational Lead
University of British Columbia
PharmaCore
![](https://www.nanomedicines.ca/wp-content/uploads/2019/05/bally-300x300.jpg)
Marcel Bally
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2023/11/Star-cropped-300x300.jpg)
Shyh-Dar (Star) Li
Core Co-Leader
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2019/11/Dos-Santos_Nancy-300x300.jpg)
Nancy Dos Santos
Core Operational Lead
BC Cancer Agency
NMIN
NHN Executive Committee (2023-24)
The Executive Committee of NMIN’s Highly Qualified Personnel (HQP) Network (NHN) is comprised of NMIN HQP, and plays a leadership role in the planning and realization of NMIN’s HQP programs, activities and other opportunities. The mandate of the NHN Executive Committee is to enhance research and professional networking opportunities for NMIN research trainees and new professionals
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Jennyfer.jpg)
Jennyfer Zapata-Farfan
PRESIDENT
Polytechnique Montréal
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Valic.jpg)
Michael Valic
VICE-PRESIDENT
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2023/06/Noorjahan.jpg)
Noorjahan Aibani
Events Director
Precision NanoSystems Inc.
![](https://www.nanomedicines.ca/wp-content/uploads/2023/06/Baker.jpg)
Alexander Baker
Member-at-large
University of Toronto
![](https://www.nanomedicines.ca/wp-content/uploads/2023/06/Amelie.jpg)
Amélie Baron
Regional Director – Quebec/Atlantic
Polytechnique Montréal
![](https://www.nanomedicines.ca/wp-content/uploads/2023/06/Tuckmantel-Bido-768x768.jpg)
Ariadne Tuckmantel Bido
Member-at-large
University of British Columbia
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Talita.jpg)
Talita de Francesco Calheiros
Member-at-large
University of Victoria
![](https://www.nanomedicines.ca/wp-content/uploads/2023/06/Chow.jpg)
Norman Chow
Communications Director
BC Cancer
![](https://www.nanomedicines.ca/wp-content/uploads/2023/06/Mandava-2-768x768.jpg)
Tavonga Mandava
Regional Director – West-Central
University of Saskatchewan
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Liza.jpg)
Liza Silverman
Regional Director – Pacific
University of Victoria
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Zia.jpg)
Nashmia Zia
Regional Director – Ontario
University of Toronto
NMIN
administration
Administrative Centre Team
The Administrative Centre team consists of the Executive Director, the Executive Assistant, the Finance Manager, the Research and Partnerships Manager, the HQP & Events Coordinator, and the Digital Initiatives Consultant. This team supports and facilitates the work of the network’s Governance, Management and Program teams, and is responsible for the network’s day-to-day operations.
![](https://www.nanomedicines.ca/wp-content/uploads/2023/05/org-chart23-920x1024.png)
![](https://www.nanomedicines.ca/wp-content/uploads/2019/09/mbeck.jpg)
Marshall Beck
Digital Initiatives / Communications Manager
email
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Cathy.jpg)
Cathy Jiang
Accountant
email
![](https://www.nanomedicines.ca/wp-content/uploads/2022/12/Rasika.jpg)
Rasika Kulkarni
Manager, Research Administration
email
Diana Royce
Executive Director
dianaroyce@nanomedicines.ca
Maria Barros
Executive Assistant
mariabarros@nanomedicines.ca
Marshall Beck
Digital Initiatives Consultant
mbeck@nanomedicines.ca
Leah Graystone
HQP & Events Coordinator
leahgraystone@nanomedicines.ca
Andrew Kim
Accountant
andrewkim@nanomedicines.ca
Daniel Rogers
Manager, Research & Partnerships
danrogers@nanomedicines.ca
NMIN
CONTACT
NMIN
2350 Health Sciences Mall, Room 5451
University of British Columbia
Vancouver, BC V6T 1Z3
Canada